skip navigation links
National Cancer Institute
EVS Logo NCI Term Browser Enterprise Vocabulary Services
Terminologies Value Sets Mappings
Version: 17.06d (Release date: 2017-06-26)
SearchBox Top
SearchBox Bottom
Patritumab (Code C78853)

Terms & Properties Synonym Details Relationships Mapping View All  
Terms & Properties

Preferred Name: Patritumab

Definition: A fully human monoclonal antibody directed against the membrane-bound receptor HER3 (ERBB3) with potential antineoplastic activity. Patritumab binds to and inhibits HER3 activation, which may result in inhibition of HER3-dependent PI3K/Akt signaling and so inhibition of cellular proliferation and differentiation. HER3, a member of the epidermal growth factor receptor (EGFR) family of receptor tyrosine kinases, is frequently overexpressed in solid tumors, including breast, lung, and colorectal tumors of epithelial origin; it has no active kinase domain itself but is activated through heterodimerization with other members of the EGFR receptor family that do.

Display Name: Patritumab

Label: Patritumab

NCI Thesaurus Code: C78853 (Search for linked caDSR metadata)  (search value sets)

NCI Metathesaurus Link: C2698144  (see NCI Metathesaurus info)

Synonyms & Abbreviations: (see Synonym Details)
AMG 888

External Source Codes: 
PDQ Closed Trial Search ID 612849
PDQ Open Trial Search ID 612849 (check for NCI PDQ open clinical trial info)
UMLS CUI C2698144

Other Properties:
     Name Value (qualifiers indented underneath)
code C78853
Contributing_Source CTRP
Legacy_Concept_Name Anti-HER3_Monoclonal_Antibody_U3-1287
Semantic_Type Pharmacologic Substance

Additional Concept Data: 
Defined Fully by Roles: No  


Mainbox Bottom